Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Single Ascending Dose Study of Selatogrel (AC-076) in Healthy Males
NCT03173625Phase 1Completed
- Sponsor
- Viatris
- Start
- Nov 2016
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of selatogrel in acute coronary syndrome (ACS) (2 arms), sponsored by Viatris. Primary endpoints: Number of participants with adverse events (AEs), Changes from baseline in electrocardiogram (ECG) variables and 2 more. Started Nov 2016; status: completed.
02
Drugs
selatogrel
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT03173625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03173625.